US › Healthcare

Prothena Corporation plc (PRTA)

US · Healthcare · Biotechnology

$8.46+2.67%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.0M

Revenue YoY

-77.1%

Net profit

$-18.6M

EPS

$-0.32

EPS estimate

$-0.39

Net margin

-1,839.9%

EPS came in at -0.32 against a street estimate of -0.39 — a beat of 17.9%.

Key statistics

Market cap

$423.0M

Forward P/E

10.6

P/B

1.49

Book value

$5.54

EPS (TTM)

$-0.81

52-week high

$11.80

52-week low

$7.73

50-day MA

$8.98

200-day MA

$9.45

Beta

-0.33

Analyst view

Analysts rate Prothena Corporation plc a buy (3 buy, 2 hold, 1 sell out of 6) with an average price target of $21.40.

Shareholding

Insiders

22.15%

Institutions

93.30%

Largest institutional holders

Fund	Stake
FMR Inc	14.71%
Rubric Capital Management LP	9.74%
BlackRock Inc	9.05%
State Street Corp	3.78%
D. E. Shaw & Co LP	3.14%
ADAR1 Capital Management LLC	3.08%
Acadian Asset Management LLC	3.01%
Vanguard Portfolio Management, LLC	2.82%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Prothena Corporation plc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.